Peter  Kaiser net worth and biography

Peter Kaiser Biography and Net Worth

Chief Development Officer of Ocular Therapeutix

Prior to joining the Ocular Therapeutix management team, Peter K. Kaiser, MD, had been the Chief Medical Advisor – Retina since 2022. Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute where he was a Heed Fellow before joining the vitreoretinal department of the Cole Eye Institute where he remains the Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine and staff surgeon.

Dr. Kaiser is actively involved in clinical research having served as Study Chairman for numerous major, multi-center, international clinical trials, and principal investigator in over 60 trials evaluating new treatments for AMD, DR, and other retinal disorders. He is the founding co-director of the Cole Eye Reading Center. Dr. Kaiser has been honored to receive the Lew R. Wasserman Award from the Research to Prevent Blindness and the Macula Society’s Young Investigator Award. He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the American Society of Retina Specialists (ASRS), and is a member of the Retina Society, Macula Society, EURETINA, and American Ophthalmological Society. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored 7 textbooks, over 30 book chapters, and more than 400 peer-reviewed manuscripts. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by American Society of Retina Specialists Honor and Senior Honor Awards, along with the American Academy of Ophthalmology Achievement, Senior Achievement, and Lifetime Achievement Awards. He has been listed as one of the “Best Doctors in America” every year since 2002 and named one of the 150 Top Innovators in Retina by Ocular Surgery News, selected as a charter inductee of the Retina Hall of Fame in 2017, and appeared on The Ophthalmologist’s Power List 2018 and 2020 as one of the top 100 most influential people in the world of ophthalmology.

What is Peter Kaiser's net worth?

The estimated net worth of Peter Kaiser is at least $2.42 million as of October 2nd, 2025. Dr. Kaiser owns 194,440 shares of Ocular Therapeutix stock worth more than $2,416,889 as of December 4th. This net worth approximation does not reflect any other investments that Dr. Kaiser may own. Learn More about Peter Kaiser's net worth.

How do I contact Peter Kaiser?

The corporate mailing address for Dr. Kaiser and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at [email protected]. Learn More on Peter Kaiser's contact information.

Has Peter Kaiser been buying or selling shares of Ocular Therapeutix?

Over the course of the past ninety days, Peter Kaiser has sold $106,472.59 in Ocular Therapeutix stock. Most recently, Peter Kaiser sold 9,653 shares of the business's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $11.03, for a transaction totalling $106,472.59. Following the completion of the sale, the insider now directly owns 194,440 shares of the company's stock, valued at $2,144,673.20. Learn More on Peter Kaiser's trading history.

Who are Ocular Therapeutix's active insiders?

Ocular Therapeutix's insider roster includes Todd Anderman (Insider), Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Peter Kaiser (Chief Development Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.

Are insiders buying or selling shares of Ocular Therapeutix?

During the last year, Ocular Therapeutix insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $69,600.00. During the last year, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 129,780 shares worth more than $1,220,159.39. The most recent insider tranaction occured on October, 8th when insider Todd Anderman sold 11,132 shares worth more than $137,368.88. Insiders at Ocular Therapeutix own 2.3% of the company. Learn More about insider trades at Ocular Therapeutix.

Information on this page was last updated on 10/8/2025.

Peter Kaiser Insider Trading History at Ocular Therapeutix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2025Sell9,653$11.03$106,472.59194,440View SEC Filing Icon  
8/25/2025Sell3,011$12.04$36,252.44204,093View SEC Filing Icon  
5/23/2025Sell2,974$7.17$21,323.58207,104View SEC Filing Icon  
See Full Table

Peter Kaiser Buying and Selling Activity at Ocular Therapeutix

This chart shows Peter Kaiser's buying and selling at Ocular Therapeutix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocular Therapeutix Company Overview

Ocular Therapeutix logo
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $12.43
Low: $11.41
High: $13.00

50 Day Range

MA: $11.63
Low: $10.63
High: $12.53

2 Week Range

Now: $12.43
Low: $5.78
High: $13.85

Volume

5,820,311 shs

Average Volume

2,330,914 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96